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Abstract
Background: Antimicrobial resistance is a serious public health problem. Fecal carriage of drug-resistant bacteria
has been suggested as an important source of antimicrobial resistant genes (ARGs). We aimed to identify risk factors
associated with fecal carriage of drug-resistant commensal Escherichia coli among healthy adult population.
Methods: We conducted a systematic review and meta-analysis following the PRISMA guideline. We identified
observational studies published from 2014 to 2019 through PubMed, Embase, and Web of Science. Studies were
eligible if they investigated and reported risk factors and accompanying measure of associations for fecal carriage of
drug-resistant E. coli for healthy population aged 18-65. Data on risk factors assessed in three or more studies were
extracted.
Results: Fifteen of 395 studies involving 11480 healthy individuals were included. The pooled prevalence of
drug-resistant Enterobacteriaceae was 14% (95% confidence interval [CI] 8-23%). Antimicrobial use within the 12
months prior to stool culture (odds ratio [OR] 1.84 [95%CI 1.35-2.51]), diarrhea symptoms (OR 1.56 [95%CI 1.09-2.25]),
travel to India (OR 4.15 [95%CI 2.54-6.78]), and vegetarian diet (OR 1.60 [95%CI 1.00(1.0043)-2.56(2.5587)]) were
associated with increased risk of fecal carriage of drug-resistant E. coli. Among travellers, antimicrobial use (OR 2.81
[95%CI 1.47-5.36]), diarrhea symptoms (OR 1.65 [95%CI 1.02-2.68]), travel to India (OR 3.80 [95%CI 2.23-6.47]), and
vegetarian diet (OR 1.92 [95%CI 1.13-3.26]) were associated with increased risk. Among general adult population,
antimicrobial use (OR 1.51 [95%CI 1.17-1.94]), diarrhea symptoms (OR 1.53 [95%CI 1.27-1.84]), and travel to Southeast
Asia (OR 1.67 [95%CI 1.02-2.73]) were associated with the increased risk of drug-resistant E. coli carriage.
Conclusions: The findings indicate that dietary habit as well as past antimicrobial use and travel to high-risk country
are associated with the risk of fecal carriage of drug-resistant commensal E. coli.
Keywords: Drug resistance, Commensal Escherichia coli, Risk factors, Systematic review, Meta-analysis
Background
Antimicrobial resistance is one of the most pressing pub-
lic health challenges of our time. In particular, the rising
incidence of infections caused by drug-resistant Gram-
negative bacteria is a serious problem due to the potential
for rapid spread of resistance via mobile elements and lim-
ited treatment options [1–3].
Among Gram-negative bacteria developing drug resis-
tance, Escherichia coli (E. coli) is the most frequent cause
of extraintestinal infections such as urinary tract infection
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and bloodstream infection [2]. Drug-resistant intestinal
pathogenic E. coli, such as Shiga toxin-producing E. coli
(STEC), are also increasingly recognized [4, 5]. E. coli can
be transmitted through contaminated water or food, or
through contact with people and other animals [6]. The
prevalence and incidence of infections caused by drug-
resistant pathogenic E. coli have been rapidly increasing
worldwide [2, 7, 8].
Major sources of drug-resistant bacteria include the
environment such as contaminated water [9], food includ-
ing meat [10, 11] and vegetables [12, 13], and healthcare
settings [14]. Additionally, intestinal commensal drug-
resistant bacteria have been reported as an important
reservoir of antimicrobial drug resistance genes (ARGs)
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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[15, 16]. Surveillance on human fecal carriage of drug-
resistant bacteria has revealed that there is an increasing
trend in intestinal ARG carriage worldwide [7, 17].
Numbers of studies have independently reported poten-
tial risk factors for the intestinal carriage of drug-resistant
bacteria. Most of these studies have found previous antibi-
otic use to be associated with drug-resistant bacteria
carriage in both primary care patients and healthy popu-
lations [18, 19]. Also, traveling to developing countries has
been identified as a risk factor for acquiring drug-resistant
bacteria [20]. Risk factors related to healthcare-associated
infections (HAI) have been reported as well, including
admission to the intensive care unit (ICU), use of catheter,
and dialysis [21–23].
E. coli is also a member of the commensal flora of
human and other warm-blooded animal intestinal tracts.
As such, they can acquire ARGs by horizontal gene trans-
fer [24] from drug-resistant E. coli strains and other
Gram-negative bacteria that enter the intestinal tract
via exposures to contaminated food, water, and other
external sources. Thus, risk factors for fecal carriage of
drug-resistant commensal E. coli and ARGs could include
exposures to environmental sources of drug-resistant bac-
teria, in addition to traditional risks such as prior use of
antibiotics.
The impact or magnitude of exposures to food on the
commensal E. coli carriage of ARGs is not known. Iden-
tifying risk factors for fecal carriage of drug-resistant
commensal E. coli associated with food could potentially
improve public health intervention to prevent the spread
of drug-resistant E. coli and ARGs. While a recent review
studied risk factors for fecal carriage of Gram-negative
bacteria expressing extended-spectrum beta-lactamase
(ESBL) reported by papers from OECD countries from
1978 to 2015 [19], there has not been a comprehensive
analysis of more recent literature reporting other resis-
tance mechanisms of human commensal E. coli.
The purpose of this review was to investigate risk fac-
tors associated with intestinal carriage of drug-resistant
commensal E. coli in the recent five years. We also aimed
to identify risk factors related to food. We focused on
the recent five years because of the increasing preva-
lence of multiple mechanisms of resistance among Gram-
negative bacteria causing extraintestinal and intestinal
infections during this period, including mechanisms such
as ESBL [25, 26], carbapenemase [27], and metallo-beta-
lactamase production [26], and plasmid-mediated colistin
resistance [28].
Methods
Data sources and search strategy
The protocol of this meta-analysis was not preregistered.
We performed a systematic review and meta-analysis
following the PRISMA [Preferred Reporting Items for
Systematic Reviews and Meta Analyses] guidelines [29]
(Additional file 2: Table S1). We conducted a litera-
ture search with the databases PubMed, Embase, and
Web of Science. We limited the search to articles pub-
lished between 2014 and 2019. Only articles published
in English were included. The search focused on risk
factors for intestinal carriages of drug-resistant com-
mensal E. coli, which was conducted on August 9th,
2019. For the purpose of this review, the definition of
antimicrobial drug resistance was based on the drug-
susceptibility test results (disk diffusion test, minimum
inhibitory concentration (MIC) test, VITEK) reported
by the clinical microbiology or research laboratories
described in the reviewed studies, which followed the
guidelines of organizations such as the Clinical and Lab-
oratory Standards Institute (CLSI). We included reports
of E. coli resistance to beta-lactams, aminoglycosides,
fluoroquinolones, and tetracyclines. We included search
terms: (feces [Title/Abstract] OR stool [Title/Abstract]
OR fecal [Title/Abstract] OR faecal [Title/Abstract]
OR “rectal swab” [Title/Abstract]) AND (“escherichia
coli” [Title/Abstract] OR escherichia [Title/Abstract]
OR “e.coli” [Title/Abstract])) AND (“drug resistant”
[Title/Abstract] OR “drug susceptible” [Title/Abstract]
OR “drug susceptibility” [Title/Abstract] OR “antimi-
crobial resistance” [Title/Abstract] OR “antimicrobial
resistant” [Title/Abstract] OR resistant [Title/Abstract]
OR resistance [Title/Abstract] OR drug [Title/Abstract]
OR multidrug [Title/Abstract]) AND (questionnaire
[Title/Abstract] OR surveillance [Title/Abstract] OR sur-
vey [Title/Abstract]).
After the databases were reviewed, the results were
exported and then compiled with the reference manage-
ment software Covidence [30]. Duplicates were removed
by automated process of Covidence, followed by a manual
search to identify and remove additional duplicates.
Study selection
All abstracts were screened first by author YH and then
by author YM to minimize omission of eligible studies.
Screening criteria were as follows: (1) examined bacteria
must include E. coli or Enterobacteriaceae; (2) examined
bacteria must be isolated from human feces, stool, or
rectal swab; (3) must report risk factors. Studies report-
ing risk factors for drug-resistant Enterobacteriaceae were
considered eligible because E. coli is the most common
Enterobacteriaceae. Studies that remained of interest were
then screened based on their full text by two indepen-
dent reviewers, YH and YM. Disagreements were resolved
by consensus. Inclusion criteria were: (1) reported risk
factor(s); (2) reported measure of associations and accom-
panying 95% confidence intervals (95% CI) or its equiv-
alent; (3) study population aged 18-65; (4) healthy study
population; (5) survey conducted after 2010.
Hu et al. Antimicrobial Resistance and Infection Control            (2020) 9:31 Page 3 of 12
For the meta-analysis, we excluded studies that (1) did
not report risk factors commonly assessed in 3 or more
studies or (2) did not offer sufficient data to create a
contingency table.
Data extraction
Data were first extracted by YH and checked by YM.
The assessment measures extracted from the included
studies were as follows: (1) publication data: lead author
names, year of publication; (2) demographic and epi-
demiological data: location of study, study population,
study design, sample size, outcome, prevalence of drug-
resistant bacteria, outcome measurement methods, sta-
tistical analysis methods; (3) risk-factor associated data:
risk factor(s) investigated, measure of associations (odds
ratios, risk ratios or prevalence ratios) and accompanying
95% CI.
When enumerating risk factors from each eligible study,
we did not limit the analysis to statistically significant
factors to avoid publication bias and to identify as many
factors studied to date as possible.
Meta-analysis
For studies which provided enough data to allow
for the creation of contingency tables, unless the
authors reported an adjusted OR and corresponding
95% CI, we manually calculated the OR and 95%
CI. If there were insufficient data to create a contin-
gency table, we excluded the study to calculate pooled
estimates.
We performed random-effects meta-analysis under a
Mantel-Haenszel model with Hartung-Knapp adjustment
to estimate the pooled effect of each commonly reported
risk factors for intestinal carriage of drug-resistant E.
coli. Mantel-Haenszel random-effects model estimates
the amount of between-study variation by comparing
each study’s result with a fixed-effect meta-analysis result
but avoids approximating Normal distributions [31, 32].
Hartung-Knapp adjustment provides a more conservative
and robust pooled OR estimates and 95% CI, allowing for
any heterogeneity between studies even when the study
number is small and study size is unequal [33]. Forest
plots were created to visualize the reported OR and 95%
CI from each studies and pooled ORs for each commonly
assessed risk factors. We assessed statistical heterogeneity
between studies by the Chi2 test and variation due to het-
erogeneity across the studies by the I2 statistic. P < 0.10
was considered indicative of statistically significant het-
erogeneity in the Chi2 test, and I2 values of 25, 50 and
75% were defined as low, moderate, and high estimates,
respectively. We evaluated the potential for publication
bias with funnel plots and Egger’s tests for meta-analyses
with at least 10 studies [34], which test for asymmetry of
the funnel plot and effects of small studies. Analyses were
conducted with R version 3.5.1 [35], with package ’meta’
version 4.9-6 [36].
Results
Study selection
Our search identified 395 unique studies that we assessed
for eligibility with title and abstract screening. Of these,
58 studies were forwarded to full-text article screen-
ing. Of the 58 full-text articles, we identified 15 rele-
vant articles that reported risk factors associated with
drug-resistant Enterobacteriaceae (10) or E. coli (5)
carriage [37–51].
Twelve of 15 studies included in the systematic review
were eligible for inclusion in the meta-analysis, which
reported sufficient data to create contingency tables to
compare risk factors that were studied in at least three
of the studies [37, 38, 40, 42–48, 50, 51]. Caudell et al.
(2018) did not report risk factors commonly assessed in 3
or more studies and Dohmen et al. (2017) and Sanneh et
al. (2018) did not offer sufficient data to create a contin-
gency table [39, 41, 49]. See Fig. 1, Table 1, and Additional
file 3: Table S2 for further details of search and reasons for
exclusion.
Study characteristics
The 15 studies represented 8 countries: England, Gambia,
Germany, Netherlands, Northern Cyprus, Singapore,
Sweden, and Tanzania (Table 1). None of the studies
reported randomization in participant selection. Eight
studies sampled volunteers from healthy general pop-
ulation that were registered to a hospital system. Five
were cohort studies of healthy travellers that compared
the prevalence of drug-resistant Enterobacteriaceae or E.
coli before and after the travel. Two studies surveyed pig
farmers.
Five studies reported prevalence of drug-resistant E.
coli, while 10 studies investigated Enterobacteriaceae. The
frequency of E. coli among Enterobacteriaceae ranged
from 79-97% for 9 studies, while one study reported 29%.
All studies collected information on demographic factors,
behaviors, and past illness from participants. Some studies
excluded insufficient response from the surveys.
The prevalence of fecal drug-resistant Enterobacteri-
aceae reported in the studies ranged from 1% to 51%.
The pooled prevalence was 14% (95% CI 8-23%) (Fig. 2a).
Nine studies reported ESBL producing Enterobacteri-
aceae. The pooled prevalence of ESBL-producing Enter-
obacteriaceae was 18% (95%CI 9-31%) (Fig. 2a). The
prevalence among general population was 8% (95%CI 4-
14%) (Fig. 2b) and among travellers was 37% (95%CI
30-43%) (Fig. 2b). All studies followed established drug
susceptibility testing methods, disc diffusion tests, VITEK
2, or minimum inhibitory concentration (MIC) measure-
ment. Common statistical methods for risk factor analysis
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Fig. 1 PRISMA Flow Diagram. Flow diagram of the systematic review process used to identify eligible studies
included univariate and multivariate logistic regression,
chi-squared test, and Fisher’s exact t test.
Commonly assessed risk factors
Commonly assessed risk factors identified in this review
are shown in Table 2. We identified fourteen risk factors
assessed in three or more studies. We assessed the pooled
ORs in the meta-analysis (Table 2, Fig. 3a, Additional
file 1: Figure S1a).
Traveling to India was the only risk factor that all studies
reported to be significantly associated with fecal carriage
of drug-resistant E. coli. For the remaining risk factors,
ORs and accompanying 95% CI were found to vary among
studies. There were three risk factors that showed signifi-
cant pooled ORs. These included antimicrobial use within
the previous 12 months (OR 1.84 [95% CI 1.35-2.51]),
diarrhea symptoms (OR 1.56 [95% CI 1.09-2.25]), and veg-
etarian diet (OR 1.60 [95% CI 1.00(1.0043)-2.56(2.5587)]).
Six (46%) of 13 studies found antimicrobial use in the
previous 12 months, 4 (57%) of 7 studies found diar-
rhea symptom, and 2 (40%) of 5 studies found vegetarian
diet to be significantly associated with the carriage of
drug-resistant bacteria.
Smoking, living with pet(s), gender, education level, pre-
vious hospital admission, proton-pump inhibitor (PPI)
use, chronic disease, international travel, travel to South-
east Asia and exposure to livestock were commonly
assessed but no significant pooled OR was found in these
studies. Of these commonly assessed risk factors, three
factors (PPI use, chronic disease, travel to Southeast Asia)
were reported as significant risks among half or more
studies included in this review. Two (67%) of 3 studies
found PPI use, 2 (67%) of 3 studies found chronic dis-
ease, and 4 (50%) of 8 studies found travel to Southeast
Asia to be significantly associated with the carriage of
drug-resistant bacteria.
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Table 1 Characteristics of studies included in review, 2014-2019
Author, year Country Study
population
Study design Study period Sample size Pathogen type
Arcilla 2017 Netherlands Travellers Prospective
cohort study
2012 Nov - 2013 Nov 1847 ESBL-PE, CPE
Angelin 2015 Sweden Travellers Prospective
study
2010 Apr - 2014 Jan 99 E. coli
Caudell 2018* Tanzania General adult Prospective
study
2012 Mar - 2015 Jul 226* E. coli
Dohmen 2017 Netherlands Employees in a
pig
slaughterhouse
Prospective
study
2015 Jun 334 E. coli
Dohmen 2017* Netherlands Pig farmers,
family members
and employees
Longitudinal
study
2011 Mar - 2011 Oct 146 ESBL-PE
Lubbert 2015 Germany Travellers Prospective
cohort study
2013 May - 2014 Apr 191 ESBL-PE
McNulty 2018 England General adult Retrospective
cohort study
2013 - 2014 2430 ESBL-PE
Miranda 2016 Germany Travellers Retrospective
study
2013 Feb - 2014 Apr 211 ESBL-PE
Mo 2019 Singapore General adult Cross sectional
study
2016 Jun - 2017 Apr 305 ESBL-PE
Reuland 2016 Netherlands General adult Case control
study
2011 Jun - 2011 Nov 1695 ESBL-PE
Reuland 2015 Netherlands General adult Case control
study
2011 Aug - 2011 Dec 550 pAmpC producing E. coli
Ruh 2019 Northern Cyprus General adult Retrospective
cohort study
2017 Sep - 2017 Dec 500 Enterobacteriaceae
Sanneh 2018* Gambia Food handlers Cross sectional
study
2015 Jul - 2015 Sep 565 Enterobacteriaceae
Vading 2016 Sweden Travellers Prospective
cohort study
2013 Apr - 2015 May 175 ESBL E. coli
Wielders 2017 Netherlands General adult Cross sectional
study
2012 Nov 2432 ESBL-PE
Note: ** not included in meta-analysis. *indicates sample size was households (all others are individuals). ESBL-PE = Extended-spectrum beta-lactamase producing
Enterobacteriaceae; CPE = Carbapenemase-producing Enterobacteriaceae
Risk factors based on travelling status
The prevalence of drug-resistant E. coli carriage suggested
two distinct populations. We divided the population into
travellers and other general population adults and repli-
cated the analysis (Table 3, Fig. 3b, c, and Additional
file 1: Figure S1b, c). Antimicrobial use within the pre-
vious 12 months, diarrhea symptoms, gender, travelling
to India, travelling to Africa, and travelling to South-
east Asia were assessed for travellers. We also assessed
antimicrobial use within the previous 12 months, diar-
rhea symptoms, gender, travelling abroad, travelling to
Southeast Asia, education status, pet, and previous hos-
pitalization among general population adults. The results
showed that antimicrobial use within the previous 12
months (OR 2.81 [95% CI 1.47-5.36]), diarrhea symptoms
(OR 1.65 [95% CI 1.02-2.68]), vegetarian diet (OR 1.92
[95% CI 1.13-3.26]), and travelling to India (OR 3.80 [95%
CI 2.23-6.47]) remained significant risk factors among
travellers. Among general population adults, antimicro-
bial use within the previous 12 months (OR 1.51 [95% CI
1.17-1.94]), diarrhea symptoms (OR 1.53 [95% CI 1.27-
1.84]), and travelling to Southeast Asia (OR 1.67 [95% CI
1.02-2.73]) were significant risk factors.
Risk factors related to food
Six of 15 studies reported risk factors related to food.
Five studies assessed the risk among vegetarians (Table 2).
As stated above, pooled OR showed significant associa-
tion with being a vegetarian (OR 1.60 [95% CI 1.00-2.56]).
Two studies reported significant association, one with
unadjusted OR [37], and another with adjusted OR [44].
Four studies reported potential food-associated risk fac-
tors other than being a vegetarian. One study reported
exposure to raw milk as significant risk factor for
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Fig. 2 Forest plots for individuals and combined prevalence estimates of fecal carriage of drug-resistant bacteria. a Prevalence of drug-resistant
Enterobacteriaceae and prevalence of ESBL-producing Enterobacteriaceae; b Prevalence of drug-resistant Enterobacteriaceae among travellers and
general populations
acquiring multi-drug-resistant E.coli (OR 7.54 [95% CI
2.41-23.45]) [39]. Two studies reported the effect of eat-
ing street food during travel. One of them was reported as
significant risk (OR 2.09 [95% CI 1.30-3.38] for daily con-
sumption; OR was 1.37 [95% CI 1.08-1.73] for occasional
consumption during travel) [37]. Another study did not
find significant association (OR 0.92 [95% CI 0.49-1.74])
[42]. Two studies assessed the effect of raw vegetable con-
sumption on the fecal carriage of drug-resistant E. coli.
One of them reported that raw vegetable consumption
during a trip to Southeast Asia significantly increased the
risk of intestinal carriage of drug-resistant Enterobacte-
riaceae (OR 2.18 [95% CI 1.29-3.68]), while exposure to
raw vegetable in South Asia significantly decreased the
risk (OR 0.34 [95% CI 0.12-0.93]) [37]. The other study
did not find any significant association (OR 0.58 [95% CI
0.33-1.07]) [43].
Bias assessment and heterogeneity evaluation
We evaluated heterogeneity among studies, and poten-
tial extent of publication bias in meta-analysis (Table 2,
Table 3, Fig. 4, Fig. 3b, and c). Funnel plots of all studies
reporting significant association (Fig. 4) were generated to
assess the potential extent of publication bias.
For pooled estimates of all studies, risk factors related
to travel showed high chi2 (11-81, P < 0.01) and I2
value (53-94%) except for travel to India. This suggests
that there was substantially high heterogeneity among
studies that examined the effect of international travel,
travel to Southeast Asia, and travel to Africa, respectively.
Smoking, PPI use, and chronic disease status also showed
moderate to high heterogeneity (I2 66-77%). For all other
risk factors, no heterogeneity was observed, suggesting
that the evidence was of high quality.
For stratified estimates among travellers, travel to Africa
and travel to Southeast Asia were the only risk factors that
showed high heterogeneity (chi2 19.27 and 41.24, respec-
tively, p < 0.01, and I2 90%). Among general adults, travel
abroad and travel to Southeast Asia showedmoderate het-
erogeneity (chi2 10.73 and 5.56, respectively, p = 0.06, and
I2 53-64%). The shapes of the funnel plots were approxi-
mately symmetrical for significant risk factors, and Egger’s
test showed p = 0.42 for antimicrobial use within the
previous 12 months among all populations included in
this study (Fig. 4). This suggests that no publication bias
existed for this factor. For all other risk factors, due to
the insufficient number of studies (less than 10 studies
for each), we did not evaluate the potential for publica-
tion bias with funnel plots and Egger’s tests for small study
effects [34].
Discussion
This study summarizes risk factors associated with intesti-
nal carriage of drug-resistant Enterobacteriaceae, in par-
ticular, E. coli among healthy adults. Our systematic
review and meta-analysis on studies published from 2014
to 2019 identified several risk factors for intestinal car-
riage of drug-resistant E. coli. We found evidence for our
hypothesis that commensal E. coli can acquire ARGs car-
ried by Gram-negative bacteria that enter the intestinal
tract from contaminated food.
We should first note that the pooled prevalence of
intestinal carriage of drug-resistant Enterobacteriaceae
in our review (14% for all Enterobacteriaceae and 18%
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Table 2 Commonly assessed risk factors for intestinal carriage of drug-resistant E. coli, 2014-2019. OR = Odds Ratio; CI = Confidence
interval. Note: *indicates results from systematic review
Risk factor Number of
studies
investigated*
Number of studies
finding significant
association*
Number
of samples
assessed
Number of samples
with drug resistant
bacteria
Pooled OR (95%CI) χ2(P-value) l2
General factors
Gender 11 1 9836 1428 1.16 (0.98-1.36) 8.77 (0.46) 0
Diet restriction (vegetarian) 5 2 6802 989 1.60 (1.00-2.56) 3.22 (0.52) 0
Pet 4 1 5159 407 1.15 (0.33-4.06) 5.23 (0.16) 43
Education level 4 0 5067 925 0.93 (0.74-1.17) 0.98 (0.81) 0
Smoking 4 1 4497 712 0.77 (0.18-3.25) 6.37 (0.04) 69
Clinical factors
Antimicrobial use 13 6 10079 1407 1.84 (1.35-2.51) 18.28 (0.05) 45
Previous hospital admission 7 2 6108 465 1.63 (0.84-3.18) 7.83 (0.17) 36
Diarrhea 7 4 5144 1079 1.56 (1.09-2.25) 5.76 (0.33) 13
Proton-pump inhibitor use 3 2 4111 359 1.31 (0.11-15.5) 5.81 (0.05) 66
Chronic disease 3 2 2323 766 0.91 (0.13-6.53) 8.68 (0.01) 77
Travel related factors
International travel 6 2 6460 520 1.13 (0.67-1.91) 10.73 (0.06) 53
Travel to Southeast Asia 8 4 6632 1289 1.78 (0.64-4.98) 50.28 (<0.01) 86
Travel to Africa 5 2 6692 1105 1.29 (0.52-3.21) 81.34 (<0.01) 94
Travel to India 4 4 2953 423 4.15 (2.54-6.78) 2.50 (0.48) 0
OR = Odds Ratio; CI = Confidence interval. Note: *indicates results from systematic review
for ESBL producing Enterobacteriaceae) has slightly
increased from an earlier review (14% [95% CI 9-20%]
for ESBL producing Enterobacteriaceae) published in
2016 [19]. Karanika et al. conducted a systematic review
and meta-analysis on papers published from 1978 to
2015 under search terms “ESBL” or “extended-spectrum
beta-lactamase”, and limited the studies conducted in
OECD countries. Our literature search was not limited
to ESBL producing bacteria nor OECD countries. Some
studies reported carbapenemase-producing Enterobac-
teriaceae (CPE), and extended-spectrum cephalosporin
(ESC) resistant E. coli. High variability in the prevalence
among studies could be explained by infections from
external sources such as the environment, contaminated
food, and contaminated water, in addition to high vari-
ability in antimicrobial usage in different regions of the
world.
The high variability could also be explained by the
types of populations studied. In our study, the preva-
lence between travellers and general adult populations
were significantly different (8% [95% CI 4-14%] and
37% [95% CI 30-43%], respectively), suggesting different
mechanisms for acquiring drug-resistant gut Enterobac-
teriaceae organisms. It is possible that travel includes
distinct behavioral activities that affect exposure to
potential risk factors for acquiring ARGs. This assumption
led us to examine the pooled estimates of OR for
each risk factor stratified by travellers vs general adult
population.
In the general adult population, we found five risk fac-
tors significantly associated with intestinal carriage of
drug-resistant E. coli, prior antimicrobial drug use within
12 months prior to stool culture, diarrhea symptoms,
travel to India, travel to Southeast Asia, and vegetarian
diet. Antimicrobial use, diarrhea symptoms, and travel
to India were also identified in previous reports [19, 20].
When controlled by travel status, we found antimicro-
bial use, diarrhea, diet and travel to India significantly
associated with fecal carriage of drug-resistant E. coli for
travellers. Travel to Southeast Asia was significantly asso-
ciated with ARG carriage only among the general adult
population. We should note that due to the limited num-
ber of studies, some risk factors commonly assessed for
entire population could not be assessed for stratified pop-
ulations. To the best of our knowledge, no previous review
has found vegetarian diet to be significantly associated
with intestinal carriage of drug-resistant E. coli. Butcher
et al. (2019) reported that unwashed vegetables could be
a source for ESBL-producing extraintestinal pathogenic
E. coli [52]. Multiple reports suggest association between
urinary pathogenic E. coli and fecal E. coli [53, 54], and
fecal carriage of drug-resistant E. coli. Although we should
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C
Fig. 3 Forest plots for significant risk factors. a Individuals and combined OR of fecal carriage of drug-resistant E. coli among entire population; b
Individuals and combined OR of fecal carriage of drug-resistant E. coli among travellers; c Individuals and combined OR of fecal carriage of
drug-resistant E. coli among general population. OR, odds ratio
note that our pooled ORs for drug-resistant E. coli intesti-
nal carriage were not controlled for potential confounding
factors other than travel status, our findings suggest that
certain type of dietary practice could be a risk factor for
acquiring drug-resistant E. coli by the gut microbiota.
In addition to the five significant risk factors, we iden-
tified ten other risk factors commonly assessed in 3 or
more reviewed studies. These include gender, smoking,
living with pet(s), education level, proton-pump inhibitor
use, previous hospital admission, chronic disease, inter-
national travel, travel to Southeast Asia, and travel to
Africa. None of these factors were significantly associated
with risk of intestinal carriage of drug-resistant E. coli.
However, 50% or more of the studies reported significant
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Table 3 Commonly assessed risk factors for intestinal carriage of drug-resistant E. coli, 2014-2019, stratified by travellers and general
adults
Travellers General adults
Risk Factor Number of
studies
investigated*
Pooled OR
(95%CI)
χ2(P-value) l2(%) Number of
studies
investigated*
Pooled OR
(95%CI)
χ2(P-value) l2(%)
General factors
Gender 4 1.14 (0.85-1.51) 2.17(0.54) 0 6 1.16 (0.90-1.50) 6.15 (0.29) 19
Diet restriction (vegetarian) 3 1.92 (1.13-3.26) 1.29 (0.52) 0 1 - - -
Pet 1 - - - 3 0.93 (0.70-1.24) 0.94 (0.63) 0
Education level 1 - - - 3 0.92 (0.63-1.35) 0.98 (0.81) 0
Clinical factors
Antimicrobial use 4 2.81 (1.47-5.36) 4.07 (0.25) 26 7 1.51 (1.17-1.94) 5.54 (0.48) 0
Previous hospital admission 1 - - - 5 1.47 (0.79-2.76) 5.54 (0.24) 28
Diarrhea 4 1.65 (1.02-2.68) 5.16 (0.16) 42 3 1.53 (1.27-1.84) 0.43 (0.80) 0
Travel related factors
International travel 0 - - - 6 1.13 (0.73-1.74) 10.73 (0.06) 53
Travel to Southeast Asia 5 1.93 (0.46-8.12) 41.24 (<0.01) 90 8 1.67 (1.02-2.73) 5.56 (0.06) 64
Travel to Africa 3 0.75 (0.29-1.96) 19.27 (<0.01) 90 2 - - -
Travel to India 3 3.80 (2.23-6.47) 1.62 (0.45) 0 1 - - -
OR = Odds Ratio; CI = Confidence interval. Note: *indicates results from systematic review
associations for proton-pump inhibitor use, chronic dis-
ease, and travel to Southeast Asia. This suggests that these
factors could serve as risks for drug-resistant E. coli colo-
nization under certain situations. In fact, travel to South-
east Asia was a significant risk factor for general adult
populations. Previous hospitalization and travel to Africa
were also assessed in the review by Karanika et al. [19].
In agreement with our findings, previous hospitalization
and travel to Africa were not significant risks. Stratifica-
tion based on location of studies such as OECD countries
to non-OECD countries and features of travel destination
such as sanitation system and antibiotics usage in food
production can alter the pooled ORs.
Multiple studies reported food as potential sources of
E. coli infections [10–13, 52]. To the best of our knowl-
edge, we found no other reviews that examined the effect
of food on fecal carriage of drug-resistant E. coli. Being
a vegetarian was significantly associated with the car-
riage of drug-resistant E. coli among overall population
and travellers. Pooled estimate among general adult pop-
ulations could not be obtained due to limited number
of studies. Several recent studies have reported con-
tamination of leafy green vegetables with saprophytic
bacteria harboring ARGs that occur in human Gram-
negative bacterial pathogens [12, 55, 56]. Four studies
reported the effect of street food, raw vegetables, and
raw milk consumption [37, 39, 42, 43]. However, these
factors showed high variance in reported ORs among
studies. This variance could be explained by differences
in study region, target population, travel destination and
sanitation conditions among studies. One study reported
conflicting ORs for raw vegetable consumption between
Southeast Asia (Brunei Darussalam, Cambodia, Indone-
sia, Lao People’s Democratic Republic, Malaysia, Myan-
mar, Philippines, Singapore, Thailand, Timor-Leste, Viet
Nam) and South Asia (Afghanistan, Bangladesh, Bhutan,
India, Iran (Islamic Republic of ), Maldives, Nepal, Pak-
istan, and Sri Lanka) [37]. Geographic differences in food
production methods and antimicrobial drug usage could
exist. Although further studies on vegetable consumption
among general population are required, this observation
suggests that dietary habit can affect fecal carriage of
drug-resistant E. coli, which supports our hypothesis that
ARGs may be acquired via contaminated food in addi-
tion to healthcare-associated acquisition and person-to-
person transmission.
There are limitations associated with this systematic
literature review. First, 10 of 15 studies investigated Enter-
obacteriaceae instead of E. coli alone. Still, the frequency
of E. coli found among studies that examined Enterobac-
teriaceae was high (79-97%) for 9 of 10 studies. One study
that had low frequency (29%) of E. coli was not eligible for
meta-analysis. Therefore, we can assume that risk factors
identified in this review would apply to E. coli. Also, we
cannot determine whether the identified risk factors have
causal effects on fecal carriage of drug-resistant E. coli.
For example, an episode of diarrhea among participants
could have prompted the use of antibiotics, which could
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Fig. 4 Funnel plots. Funnel plots for studies reporting antimicrobial use, diarrhea, vegetarian diet, and travel to India as risk factors
have selected for drug-resistant E. coli in the host intesti-
nal microbiota. Still, identification of factors significantly
associated with the carriage of drug-resistant E. coliwill be
useful for identifying individuals with high risk and early
focused interventions. Another limitation of our study is
that there was no study from North America included
in this review. Karanika et al. (2016) reported the same
limitation [19]. Since North America is a major food-
exporting region in which antibiotics are heavily used
in food animal husbandry and agriculture, if food is an
important reservoir for drug-resistant bacteria that enter
our intestines, more studies in this geographic region are
needed. Also, although we did not observe publication
bias for risk factors identified in this study, we found
high heterogeneity among studies that reported the risk
of chronic disease and travel related factors on intestinal
carriage of drug-resistant bacteria. This high heterogene-
ity could be explained by differences in samplingmethods,
chronic diseases reported, travel destinations, and sanita-
tion conditions examined in the studies. These differences
could have affected the pooled OR estimates. Particularly,
we should note that the chronic diseases three studies
investigated were different among studies, and there was a
high variation in disease incidence within the studies [37,
45, 50]. Furthermore, there were three studies reporting
association for PPI use as risk factors for fecal carriage
of drug-resistant E. coli [46, 50, 51], and McNulty et al.
(2018) stated in their limitation that they did not collect
data on the use of PPI [43]. Since PPI use is one of the indi-
cators of chronic disease, larger studies related to PPI use
and other chronic diseases may alter the result.
Conclusion
In this review, we found five significant risk factors
associated with intestinal carriage of drug-resistant E.
coli, antimicrobial use, diarrhea, vegetarian diet, travel to
India, and travel to Southeast Asia. Due to the high het-
erogeneity of the studies, other factors may indeed serve
as risks under certain circumstances. Further studies,
especially those that examine food and other environ-
mental exposures will be essential for identifying public
health interventions that can be devised to decrease
human intestinal colonization with drug-resistant
bacteria.
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